Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Experts blaze TRAIL for pulmonary arterial hypertension therapy

Researchers have shown that the cell signaling molecule tumor necrosis factor-related apoptosis-inducing ligand may be a potential therapeutic target for pulmonary arterial hypertension.

16 Oct 2012

Gravity changes affect immune system development

New research findings recently published in The FASEB Journal, show that immune system development is affected by gravity changes, as reported by researchers from the University of Lorraine and University of Luxembourg. Astronauts are exposed to stresses, during launch and landing, which disrupts their body's natural defenses against infection. Changes to the immune system need to be investigated before astronauts undergo longer space missions.

16 Oct 2012

Current status, challenges and opportunities of pulmonary vaccine delivery

In addition to the obvious benefit of eliminating the need for an injection, new vaccine delivery methods via the lungs offer particular advantages for protecting against infectious agents that enter the body through the respiratory track.

16 Oct 2012

Therapeutic HPV16 and HPV18 vaccine ‘may eliminate infection’

A candidate vaccine against human papillomavirus serotypes 16 and 18 appears to induce robust immune responses to antigens, potentially leading to the elimination of virus-infected cells and regression of dysplasia, say US investigators.

15 Oct 2012

New findings on Alzheimer's disease presented at Neuroscience 2012

Curtailing the imminent rise in Alzheimer's disease (AD) will require early, accurate diagnostic tests and treatments, and researchers are closer to achieving these two goals. New findings in medical imaging, molecular analysis of neurological diseases, and development of treatments using mouse models were presented at Neuroscience 2012, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

15 Oct 2012

FIGHT HLH Consortium receives EUR 6 million FP7 grant for testing NovImmune's NI-0501

NovImmune SA announced that the European Commission has awarded a 6 million Euros FP7 grant to the "FIGHT HLH" consortium of institutions to support clinical testing of NovImmune's anti-interferon gamma drug candidate, NI-0501.

15 Oct 2012

Pioneering research paves way for new treatments for pulmonary arterial hypertension

Pioneering research conducted by the University of Sheffield is paving the way for new treatments which could benefit patients suffering from the fatal lung disease pulmonary arterial hypertension (PAH).

15 Oct 2012

Highlights of Mount Sinai research at Neuroscience 2012

Researchers from Mount Sinai School of Medicine are presenting important discoveries on the involvement of the immune system and dopamine cells in the onset of depression at Neuroscience 2012, the Society for Neuroscience's 42nd annual meeting on October 13 -17 in New Orleans, and are available for interviews.

15 Oct 2012

FDA expands approved indication for Genentech’s ACTEMRA to treat active rheumatoid arthritis

Genentech, Inc., a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ACTEMRA (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

13 Oct 2012

Women respond much better than men to treatment of CFL with rituximab

Women respond much better than men to the treatment of chronic follicular lymphoma with a monoclonal antibody that targets CD20 (rituximab). These are the findings of a multi-centre, Austria-wide study by the Arbeitsgemeinschaft medikamentöse Tumortherapie (AGMT) carried out under the supervision of the University Department of Internal Medicine I and study leader Ulrich Jäger, which has now been published in the highly respected journal "Haematologica".

11 Oct 2012

Leading scientists select first drugs to be evaluated in Alzheimer's clinical study

Leading scientists have selected the first drugs to be evaluated in a worldwide clinical study to determine whether they can prevent Alzheimer's disease.

11 Oct 2012

Ranibizumab improves driving prospects for AMD patients

Treatment with ranibizumab can preserve and even improve the perceived driving ability of patients with age-related macular degeneration, show the results of two randomized trials.

10 Oct 2012

Mayo researchers discover new therapy for patients with neuromyelitis optica

Mayo Clinic researchers have identified a new therapy for patients with neuromyelitis optica that appears to stop inflammation of the eye nerves and spinal cord. NMO is a debilitating central nervous system disorder that is often misdiagnosed as multiple sclerosis (MS).

10 Oct 2012

CRI, MedImmune partner to advance cancer immunotherapy research

The Cancer Research Institute (CRI), the Ludwig Institute for Cancer Research and MedImmune, the global biologics arm of AstraZeneca, today announced that they have signed a collaboration agreement to advance the research of immunotherapy in cancer.

10 Oct 2012

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML).

9 Oct 2012

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Genzyme, a Sanofi company, announced today new data from Genzyme's clinical development programs for AUBAGIO (teriflunomide) and LEMTRADATM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.

9 Oct 2012

Liquorice-based nanotech material for sterilizing medical devices

A nanotech material containing an extract from liquorice can be used to sterilize and protect medical devices and implants which include biological components, and protects these functional bio-components during the sterilization process.

8 Oct 2012

ImaginAb enters into neurodegeneration research collaboration agreement with Lundbeck

ImaginAb, Inc., a clinical-stage company developing in vivo molecular imaging agents based on antibody fragment technology, today announced that it has entered into a collaboration and commercialization agreement with H. Lundbeck A/S.

8 Oct 2012

Trellis, OMT enter collaboration to generate human antibodies

Trellis Bioscience LLC and Open Monoclonal Technology, Inc. today announced a new collaboration where the companies will join forces to generate human antibodies against therapeutic targets identified by Trellis and its partners using OMT's OmniRat platform.

8 Oct 2012

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract and a Phase 2 option from the National Cancer Institute (NCI) valued up to $1,683,503.

8 Oct 2012